Search > Results
You searched for: EV170036 (EV-TRACK ID)
Showing 1 - 12 of 12
Showing 1 - 12 of 12
Details | EV-TRACK ID | Experiment nr. | Species | Sample type | Separation protocol | First author | Year | EV-METRIC |
---|---|---|---|---|---|---|---|---|
EV170036 | 8/12 | Homo sapiens | Serum |
(d)(U)C Filtration |
Krafft C | 2017 | 28% | |
Study summaryFull title
All authors
Krafft C, Wilhelm K, Eremin A, Nestel S, von Bubnoff N, Schultze-Seemann W, Popp J, Nazarenko I
Journal
J Cell Sci
Abstract
In cancer, extracellular vesicles (EV) contribute to tumor progression by regulating local and syste (show more...)
EV-METRIC
28% (70th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Serum
Sample origin
Benign prostate hyperplasia
Focus vesicles
EV12
Separation protocol
Separation protocol
(d)(U)C
Filtration Adj. k-factor
213.2 (pelleting)
Protein markers
EV: None
non-EV: None Proteomics
no
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Serum
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 100,000 g and 150,000 g Pelleting performed
Yes
Pelleting: time(min)
90
Pelleting: rotor type
SW 41 Ti
Pelleting: speed (g)
120000
Pelleting: adjusted k-factor
213.2
Filtration steps
0.22µm or 0.2µm
EV-subtype
Distinction between multiple subtypes
we proceeded with IR and RAMAN analysis of EVs isolated by 12000 x g (frequently designated as micro
Characterization: Protein analysis
None
Protein Concentration Method
microBCA
Protein Yield (µg)
4-6 for healty donors in EV12; 100 in cancer patients;
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Size range/distribution
Reported size (nm)
30-200
Particle yield
1.10E+11 particles/ml start sample
EM
EM-type
Transmission-EM
Image type
Wide-field
Other particle analysis name(1)
Raman spectroscopy
|
||||||||
EV170036 | 10/12 | Homo sapiens | Serum |
(d)(U)C Filtration |
Krafft C | 2017 | 28% | |
Study summaryFull title
All authors
Krafft C, Wilhelm K, Eremin A, Nestel S, von Bubnoff N, Schultze-Seemann W, Popp J, Nazarenko I
Journal
J Cell Sci
Abstract
In cancer, extracellular vesicles (EV) contribute to tumor progression by regulating local and syste (show more...)
EV-METRIC
28% (70th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Serum
Sample origin
Prostate cancer
Focus vesicles
EV120
Separation protocol
Separation protocol
(d)(U)C
Filtration Adj. k-factor
213.2 (pelleting)
Protein markers
EV: None
non-EV: None Proteomics
no
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Serum
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 100,000 g and 150,000 g Pelleting performed
Yes
Pelleting: time(min)
90
Pelleting: rotor type
SW 41 Ti
Pelleting: speed (g)
120000
Pelleting: adjusted k-factor
213.2
Filtration steps
0.22µm or 0.2µm
EV-subtype
Distinction between multiple subtypes
we proceeded with IR and RAMAN analysis of EVs isolated by 12000 x g (frequently designated as micro
Characterization: Protein analysis
None
Protein Concentration Method
microBCA
Protein Yield (µg)
4-6 for healty donors in EV12; 100 in cancer patients;
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Size range/distribution
Reported size (nm)
30-200
Particle yield
1.00E+11 particles/ml start sample
EM
EM-type
Transmission-EM
Image type
Wide-field
Other particle analysis name(1)
Raman spectroscopy
|
||||||||
EV170036 | 1/12 | Homo sapiens | Blood plasma | (d)(U)C | Krafft C | 2017 | 14% | |
Study summaryFull title
All authors
Krafft C, Wilhelm K, Eremin A, Nestel S, von Bubnoff N, Schultze-Seemann W, Popp J, Nazarenko I
Journal
J Cell Sci
Abstract
In cancer, extracellular vesicles (EV) contribute to tumor progression by regulating local and syste (show more...)
EV-METRIC
14% (38th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Blood plasma
Sample origin
Prostate cancer
Focus vesicles
EV12
Separation protocol
Separation protocol
(d)(U)C
Protein markers
EV: None
non-EV: None Proteomics
no
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Blood plasma
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 10,000 g and 50,000 g Pelleting performed
Yes
Pelleting: time(min)
90
Pelleting: speed (g)
12000
Characterization: Protein analysis
None
Protein Concentration Method
microBCA
Protein Yield (µg)
311
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Size range/distribution
Reported size (nm)
30-150
EV concentration
Yes
Particle yield
1.55E+10 particles/ml start sample
EM
EM-type
Transmission-EM
Image type
Wide-field
Other particle analysis name(1)
Raman spectroscopy
|
||||||||
EV170036 | 2/12 | Homo sapiens | Serum | (d)(U)C | Krafft C | 2017 | 14% | |
Study summaryFull title
All authors
Krafft C, Wilhelm K, Eremin A, Nestel S, von Bubnoff N, Schultze-Seemann W, Popp J, Nazarenko I
Journal
J Cell Sci
Abstract
In cancer, extracellular vesicles (EV) contribute to tumor progression by regulating local and syste (show more...)
EV-METRIC
14% (56th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Serum
Sample origin
Control condition
Focus vesicles
EV12
Separation protocol
Separation protocol
(d)(U)C
Protein markers
EV: None
non-EV: None Proteomics
no
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Serum
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 10,000 g and 50,000 g Pelleting performed
Yes
Pelleting: time(min)
90
Pelleting: speed (g)
12000
Characterization: Protein analysis
None
Protein Concentration Method
microBCA
Protein Yield (µg)
11.4
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Size range/distribution
Reported size (nm)
30-150
EV concentration
Yes
Particle yield
1.34E+10 particles/ml start sample
EM
EM-type
Transmission-EM
Image type
Wide-field
Other particle analysis name(1)
Raman spectroscopy
|
||||||||
EV170036 | 3/12 | Homo sapiens | Blood plasma |
(d)(U)C Filtration |
Krafft C | 2017 | 14% | |
Study summaryFull title
All authors
Krafft C, Wilhelm K, Eremin A, Nestel S, von Bubnoff N, Schultze-Seemann W, Popp J, Nazarenko I
Journal
J Cell Sci
Abstract
In cancer, extracellular vesicles (EV) contribute to tumor progression by regulating local and syste (show more...)
EV-METRIC
14% (38th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Blood plasma
Sample origin
Prostate cancer
Focus vesicles
EV120
Separation protocol
Separation protocol
(d)(U)C
Filtration Adj. k-factor
213.2 (pelleting)
Protein markers
EV: None
non-EV: None Proteomics
no
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Blood plasma
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 100,000 g and 150,000 g Pelleting performed
Yes
Pelleting: time(min)
90
Pelleting: rotor type
SW 41 Ti
Pelleting: speed (g)
120000
Pelleting: adjusted k-factor
213.2
Filtration steps
0.22µm or 0.2µm
EV-subtype
Distinction between multiple subtypes
we proceeded with IR and RAMAN analysis of EVs isolated by 12000 x g (frequently designated as micro
Characterization: Protein analysis
None
Protein Concentration Method
microBCA
Protein Yield (µg)
4-6 for healty donors in EV12; 100 in cancer patients;
Characterization: Lipid analysis
No
Characterization: Particle analysis
Other particle analysis name(1)
Raman spectroscopy
|
||||||||
EV170036 | 4/12 | Homo sapiens | Blood plasma | (d)(U)C | Krafft C | 2017 | 14% | |
Study summaryFull title
All authors
Krafft C, Wilhelm K, Eremin A, Nestel S, von Bubnoff N, Schultze-Seemann W, Popp J, Nazarenko I
Journal
J Cell Sci
Abstract
In cancer, extracellular vesicles (EV) contribute to tumor progression by regulating local and syste (show more...)
EV-METRIC
14% (38th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Blood plasma
Sample origin
Prostate cancer
Focus vesicles
EV120
Separation protocol
Separation protocol
(d)(U)C
Protein markers
EV: None
non-EV: None Proteomics
no
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Blood plasma
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 10,000 g and 50,000 g Between 100,000 g and 150,000 g Pelleting performed
Yes
Pelleting: time(min)
90
Pelleting: speed (g)
120000
Characterization: Protein analysis
None
Protein Concentration Method
microBCA
Protein Yield (µg)
311
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Size range/distribution
Reported size (nm)
30-150
EV concentration
Yes
Particle yield
4.28E+10 particles/ml start sample
EM
EM-type
Transmission-EM
Image type
Wide-field
Other particle analysis name(1)
Raman spectroscopy
|
||||||||
EV170036 | 5/12 | Homo sapiens | Blood plasma | (d)(U)C | Krafft C | 2017 | 14% | |
Study summaryFull title
All authors
Krafft C, Wilhelm K, Eremin A, Nestel S, von Bubnoff N, Schultze-Seemann W, Popp J, Nazarenko I
Journal
J Cell Sci
Abstract
In cancer, extracellular vesicles (EV) contribute to tumor progression by regulating local and syste (show more...)
EV-METRIC
14% (38th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Blood plasma
Sample origin
Control condition
Focus vesicles
EV120
Separation protocol
Separation protocol
(d)(U)C
Protein markers
EV: None
non-EV: None Proteomics
no
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Blood plasma
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 10,000 g and 50,000 g Between 100,000 g and 150,000 g Pelleting performed
Yes
Pelleting: time(min)
90
Pelleting: speed (g)
120000
Characterization: Protein analysis
None
Protein Concentration Method
microBCA
Protein Yield (µg)
9.4
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Size range/distribution
Reported size (nm)
30-150
EV concentration
Yes
Particle yield
1.86E+10 particles/ml start sample
EM
EM-type
Transmission-EM
Image type
Wide-field
Other particle analysis name(1)
Raman spectroscopy
|
||||||||
EV170036 | 6/12 | Homo sapiens | Serum | (d)(U)C | Krafft C | 2017 | 14% | |
Study summaryFull title
All authors
Krafft C, Wilhelm K, Eremin A, Nestel S, von Bubnoff N, Schultze-Seemann W, Popp J, Nazarenko I
Journal
J Cell Sci
Abstract
In cancer, extracellular vesicles (EV) contribute to tumor progression by regulating local and syste (show more...)
EV-METRIC
14% (56th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Serum
Sample origin
Control condition
Focus vesicles
EV120
Separation protocol
Separation protocol
(d)(U)C
Protein markers
EV: None
non-EV: None Proteomics
no
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Serum
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 10,000 g and 50,000 g Between 100,000 g and 150,000 g Pelleting performed
Yes
Pelleting: time(min)
90
Pelleting: speed (g)
120000
Characterization: Protein analysis
None
Protein Concentration Method
microBCA
Protein Yield (µg)
1273
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Size range/distribution
Reported size (nm)
30-150
EV concentration
Yes
Particle yield
1.69E+10 particles/ml start sample
EM
EM-type
Transmission-EM
Image type
Wide-field
Other particle analysis name(1)
Raman spectroscopy
|
||||||||
EV170036 | 7/12 | Homo sapiens | Serum | (d)(U)C | Krafft C | 2017 | 14% | |
Study summaryFull title
All authors
Krafft C, Wilhelm K, Eremin A, Nestel S, von Bubnoff N, Schultze-Seemann W, Popp J, Nazarenko I
Journal
J Cell Sci
Abstract
In cancer, extracellular vesicles (EV) contribute to tumor progression by regulating local and syste (show more...)
EV-METRIC
14% (56th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Serum
Sample origin
Prostate cancer
Focus vesicles
EV120
Separation protocol
Separation protocol
(d)(U)C
Protein markers
EV: None
non-EV: None Proteomics
no
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Serum
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 10,000 g and 50,000 g Between 100,000 g and 150,000 g Pelleting performed
Yes
Pelleting: time(min)
90
Pelleting: speed (g)
120000
Characterization: Protein analysis
None
Protein Concentration Method
microBCA
Protein Yield (µg)
839.6
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Size range/distribution
Reported size (nm)
30-150
EV concentration
Yes
Particle yield
4.84E+10 particles/ml start sample
EM
EM-type
Transmission-EM
Image type
Wide-field
Other particle analysis name(1)
Raman spectroscopy
|
||||||||
EV170036 | 9/12 | Homo sapiens | Blood plasma |
(d)(U)C Filtration |
Krafft C | 2017 | 14% | |
Study summaryFull title
All authors
Krafft C, Wilhelm K, Eremin A, Nestel S, von Bubnoff N, Schultze-Seemann W, Popp J, Nazarenko I
Journal
J Cell Sci
Abstract
In cancer, extracellular vesicles (EV) contribute to tumor progression by regulating local and syste (show more...)
EV-METRIC
14% (38th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Blood plasma
Sample origin
Benign prostate hyperplasia
Focus vesicles
EV12
Separation protocol
Separation protocol
(d)(U)C
Filtration Adj. k-factor
213.2 (pelleting)
Protein markers
EV: None
non-EV: None Proteomics
no
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Blood plasma
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 100,000 g and 150,000 g Pelleting performed
Yes
Pelleting: time(min)
90
Pelleting: rotor type
SW 41 Ti
Pelleting: speed (g)
120000
Pelleting: adjusted k-factor
213.2
Filtration steps
0.22µm or 0.2µm
EV-subtype
Distinction between multiple subtypes
we proceeded with IR and RAMAN analysis of EVs isolated by 12000 x g (frequently designated as micro
Characterization: Protein analysis
None
Protein Concentration Method
microBCA
Protein Yield (µg)
4-6 for healty donors in EV12; 100 in cancer patients;
Characterization: Lipid analysis
No
Characterization: Particle analysis
Other particle analysis name(1)
Raman spectroscopy
|
||||||||
EV170036 | 11/12 | Homo sapiens | Serum | (d)(U)C | Krafft C | 2017 | 14% | |
Study summaryFull title
All authors
Krafft C, Wilhelm K, Eremin A, Nestel S, von Bubnoff N, Schultze-Seemann W, Popp J, Nazarenko I
Journal
J Cell Sci
Abstract
In cancer, extracellular vesicles (EV) contribute to tumor progression by regulating local and syste (show more...)
EV-METRIC
14% (56th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Serum
Sample origin
Prostate cancer
Focus vesicles
EV12
Separation protocol
Separation protocol
(d)(U)C
Protein markers
EV: None
non-EV: None Proteomics
no
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Serum
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 10,000 g and 50,000 g Pelleting performed
Yes
Pelleting: time(min)
90
Pelleting: speed (g)
12000
Characterization: Protein analysis
None
Protein Concentration Method
microBCA
Protein Yield (µg)
255.2
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Size range/distribution
Reported size (nm)
30-150
EV concentration
Yes
Particle yield
2.24E+10 particles/ml start sample
EM
EM-type
Transmission-EM
Image type
Wide-field
Other particle analysis name(1)
Raman spectroscopy
|
||||||||
EV170036 | 12/12 | Homo sapiens | Blood plasma | (d)(U)C | Krafft C | 2017 | 14% | |
Study summaryFull title
All authors
Krafft C, Wilhelm K, Eremin A, Nestel S, von Bubnoff N, Schultze-Seemann W, Popp J, Nazarenko I
Journal
J Cell Sci
Abstract
In cancer, extracellular vesicles (EV) contribute to tumor progression by regulating local and syste (show more...)
EV-METRIC
14% (38th percentile of all experiments on the same sample type)
Reported
Not reported Not applicable EV-enriched
proteins
Protein analysis: analysis of three or more EV-enriched proteins
non
EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative
and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron
microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density
gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody
specifics
Protein analysis: antibody clone/reference number and dilution
lysate
preparation
Protein analysis: lysis buffer composition
Study dataSample type
Blood plasma
Sample origin
Control condition
Focus vesicles
EV12
Separation protocol
Separation protocol
(d)(U)C
Protein markers
EV: None
non-EV: None Proteomics
no
Show all info
Study aim
Biomarker
Sample
Species
Homo sapiens
Sample Type
Blood plasma
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 10,000 g and 50,000 g Pelleting performed
Yes
Pelleting: time(min)
90
Pelleting: speed (g)
12000
Characterization: Protein analysis
None
Protein Concentration Method
microBCA
Protein Yield (µg)
9.4
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Size range/distribution
Reported size (nm)
30-150
EV concentration
Yes
Particle yield
4.26E+09 particles/ml start sample
EM
EM-type
Transmission-EM
Image type
Wide-field
Other particle analysis name(1)
Raman spectroscopy
|
||||||||
1 - 12 of 12 |
EV-TRACK ID | EV170036 | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
species | Homo sapiens | |||||||||||
sample type | Serum | Serum | Blood plasma | Serum | Blood plasma | Blood plasma | Blood plasma | Serum | Serum | Blood plasma | Serum | Blood plasma |
condition | Benign prostate hyperplasia | Prostate cancer | Prostate cancer | Control condition | Prostate cancer | Prostate cancer | Control condition | Control condition | Prostate cancer | Benign prostate hyperplasia | Prostate cancer | Control condition |
separation protocol | (d)(U)C Filtration | (d)(U)C Filtration | (d)(U)C | (d)(U)C | (d)(U)C Filtration | (d)(U)C | (d)(U)C | (d)(U)C | (d)(U)C | (d)(U)C Filtration | (d)(U)C | (d)(U)C |
vesicle related term | EV12 | EV120 | EV12 | EV12 | EV120 | EV120 | EV120 | EV120 | EV120 | EV12 | EV12 | EV12 |
Exp. nr. | 8 | 10 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 9 | 11 | 12 |
EV-METRIC % | 28 | 28 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 | 14 |